Atopic DermatitisFeatured PodcastPodcast Highlights

Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

By March 30, 2021April 1st, 2022No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

Drs. April Armstrong, Lawrence Eichenfield & Adam Friedman

 

The Ps of Lichen Planus got nothing on this alliteration filled podcast that was purposefully positioned to perfect your practice prowess to punish the pruritus and picking of AD. Join host Dr. Adam Friedman in part four of five of this Atopic Dermatitis dedicated series as he parties with and picks the brains of dermatology powerhouses Dr.s April Armstrong and Lawrence Eichenfield on pursuing a practical and powerful process to partner with patients of all ages and partake in a long standing management strategy. Please do not push this one off – I promise it is educational perfection. (That’s 24 Ps!)
Listen Now
Learning Objectives
Upon completion of this podcast participants should be able to:

  • Discuss management strategies for patients with moderate-to-severe atopic dermatitis
  • Identify common co-morbidities of atopic dermatitis and strategies for optimal patient care
This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.
Disclosures

April W. Armstrong, MD, MPH – No disclosures.

Lawrence F. Eichenfield, MD – Grant/Research Support: Abbvie, Pfizer, Regeneron, Sanofi-Genzyme, Ortho Derm, Verrica. Consultant: Almirall, Arcutis, Asana, Dermavant, Dermira, Forte, Galderma, Incyte, Leo Pharma, Lilly, Novartis, OrthoDerm. Speakers’ Bureau: Pfizer, Regeneron, Sanofi-Genzyme.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

You May Also Like

Wondering about Words: Evidence Based Framing for Improving Treatment Adherence

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Hosts: Dr. Adam Friedman and Dr. Steven Feldman Actions speak louder than words…so long as the words inspire, encourage, engage, etc. the actions. This…

Prevention is the Best Medicine: ADing up the Data

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Dr. Candrice Heath, Dr. Jonathan O’B. Hourihane & Dr. Adam Friedman Atopic Dermatitis (AD) is the second most common chronic inflammatory (coming for you…

See Ya ciAREs: A Review of Mitigation and Management Strategies for Immunotherapy Associated Skin Scares

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Dr. Beth McLellan & Adam Friedman, MD, FAAD Mo’ targeted therapies, mo’skin problems. Some may say, “Bring on the problems” – but why should they…

Leave a Reply